Renalytix plc (LSE:RENX) develops and commercialises prognostic testing for kidney disease. Its lead product assesses the risk of rapid decline in kidney function among adults with type 2 diabetes and early-stage chronic kidney disease, combining blood-based markers with clinical record data. The test has …
Fusion Antibodies plc (LSE:FAB) provides contract research services to drug developers, specialising in antibody engineering, humanisation, characterisation and related preclinical work. Its clients are typically biotechnology companies advancing therapeutic candidates towards clinical development. The case depends heavily on the funding environment for those clients, …
IXICO plc (LSE:IXI) supplies neuroscience imaging and biomarker analytics to companies and institutions developing treatments for neurological disorders. Its platform measures imaging markers associated with conditions such as Alzheimer’s, Huntington’s and Parkinson’s diseases. TheInvestmentcase combines a specialised serviceBusinesswith an ambition to license technology more …
Worldwide Healthcare Trust plc shares rose 0.13% today to around 380.00p, extending a period of renewed strength for the specialist global healthcareInvestmenttrust following a strong return to form in its most recent financial year.
SkinBioTherapeutics Plc (LSE:SBTX), quoted on the London Stock Exchange’s AIM market, develops and commercialises skin-health products and technology. Its activities combine topical skincare, oral supplements, licensing and contract manufacturing. Investor sentiment remains vulnerable because commercial growth has yet to establish sustainable profitability. For smaller …
The supplied market snapshot indicates a -5.88% decline. No verified announcement establishing the cause of that session’s movement was identified, so attributing the fall to a fresh operational setback or institutional selling would be speculative.
The supplied market snapshot shows ImmuPharma down by -8.30%. A definitive company-specific cause for that session’s movement could not be independently established. Funding sensitivity, uncertainPartnershiptiming and speculative selling are plausible interpretations rather than confirmed explanations.
Abingdon Health Plc (LSE:ABDX) develops and manufactures rapid diagnostic tests and provides associated technical and regulatory services. Its shares trade on the London Stock Exchange’s AIM market. TheBusinessoffers exposure to outsourced diagnostic development, but customer funding, technical milestones and commercialisation schedules can make revenue …
Diaceutics PLC is attracting attention on 22 September 2026 because the company is scheduled to report its unaudited results for the six months ended 30 June 2026.
EDX Medical Group LSE:EDX is attracting attention after gaining8.33% on 22 September 2026, making it one of the stronger healthcare movers in the UK market list being monitored.